Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Result of Annual General Meeting
8 March 2024 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces that all resolutions proposed at the 2023 Annual General Meeting ("AGM") held today were duly passed by shareholders by way of poll vote.
Resolutions 1 to 11 (inclusive) were proposed as ordinary resolutions and resolutions 12 to 14 (inclusive) were proposed as special resolutions. The results of the proxy votes received ahead of the meeting are outlined in the table below.
| Resolution | For: | %age | Against: | %age | Total Votes Cast | Withheld |
| 1. Approval of 2023 Accounts | 4,454,427,655 | 100.00% | 100,000 | 0.00% | 4,454,529,660 | 2,005 |
| 2. Approval of Directors' Remuneration Report | 4,440,353,568 | 99.68% | 14,174,087 | 0.32% | 4,454,529,660 | 2,005 |
| 3. To re-elect Mary Tavener as a Director | 4,454,239,121 | 99.99% | 278,279 | 0.01% | 4,454,529,660 | 12,260 |
| 4. To re-elect Tunde Otulana as a Director | 4,454,384,117 | 100.00% | 133,283 | 0.00% | 4,454,529,660 | 12,260 |
| 5. To re-elect Manuel Llobet as a Director | 4,454,284,117 | 99.99% | 233,283 | 0.01% | 4,454,529,660 | 12,260 |
| 6. To re-elect Cheryl MacDiarmid as a Director | 4,454,384,117 | 100.00% | 133,283 | 0.00% | 4,454,529,660 | 12,260 |
| 7. To re-elect Peter Jensen O.B.E. as a Director | 4,440,494,882 | 99.69% | 14,015,154 | 0.31% | 4,454,529,660 | 19,624 |
| 8. To re-appoint BDO LLP as auditors of the Company | 4,454,306,655 | 100.00% | 221,000 | 0.00% | 4,454,529,660 | 2,005 |
| 9. To authorise the Directors to agree the Auditors remuneration | 4,454,415,654 | 100.00% | 108,001 | 0.00% | 4,454,529,660 | 6,005 |
| 10. To authorise the Directors to allot the unissued share capital up to a specific amount (s.551) | 4,454,236,175 | 99.99% | 291,480 | 0.01% | 4,454,529,660 | 2,005 |
| 11. Authority to issue warrants | 4,440,359,504 | 99.68% | 14,168,151 | 0.32% | 4,454,529,660 | 2,005 |
| 12. Special Resolution: To authorise the Directors to allot equity securities for cash without first being required to offer such shares to existing shareholders for a period expiring at the conclusion of the next annual general meeting of the Company or 31 December 2024, whichever occurs first. | 4,440,458,304 | 99.68% | 14,069,351 | 0.32% | 4,454,529,660 | 2,005 |
| 13. Special Resolution: To authorise the Directors to allot equity securities and/or sell treasury shares for cash without first being required to offer such securities to existing shareholders | 4,440,458,304 | 99.68% | 14,069,351 | 0.32% | 4,454,529,660 | 2,005 |
| 14. Special Resolution: Disapplication of pre-emption rights in relation to the Warrants | 4,440,428,445 | 99.68% | 14,095,210 | 0.32% | 4,454,529,660 | 6,005 |
- ENDS -
Allergy Therapeutics
Manuel Llobet, Chief Executive Officer
Shaun Furlong, Chief Financial Officer
+44 (0)1903 845 820
Panmure Gordon (Nominated Adviser and Broker)
Emma Earl, Mark Rogers, Freddy Crossley, Corporate Finance
Rupert Dearden, Corporate Broking
+44 (0)20 7886 2500
ICR Consilium
Mary-Jane Elliott / David Daley / Davide Salvi
+44 (0)20 3709 5700
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
